Sugi Predict

Sugi Predict / Compounds / SCHEMBL10210591

SCHEMBL10210591

SCHEMBL10210591

CCOC(=O)CC[C@@H](N)/C=C/[C@@H](O)Cc1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ PPARG P37231 2/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ CYP4F2 P78329 1/20 0.39
▸ CYP4A11 Q02928 1/20 0.39
▸ NOS2 P35228 2/20 0.38
▸ NOS3 P29474 1/20 0.38
▸ NOS1 P29475 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12226221 0.85 NPSR1 (0.42) NPSR1MAPTCYP1A2MEN1LMNA
SCHEMBL4902813 0.82 L3MBTL1 (0.37) CYP1A2KMT2ACYP4F2CYP4A11POLB
Hydrochloric Acid SCHEMBL4902819 0.81 L3MBTL1 (0.36) CYP1A2KMT2ACYP4F2CYP4A11POLB
Hydrochloric Acid SCHEMBL4902808 0.81 L3MBTL1 (0.36) CYP1A2KMT2ACYP4F2CYP4A11POLB
Hydrochloric Acid SCHEMBL1401248 0.81 FFAR1 (0.42) MEN1KMT2ACYP2C19
Hydrochloric Acid SCHEMBL1401243 0.81 FFAR1 (0.42) MEN1KMT2ACYP2C19
SCHEMBL13148452 0.81 CYP4Z1 (0.41) NPSR1MAPTCYP1A2MEN1LMNA
SCHEMBL11929411 0.79 HPGD (0.38) LMNAHPGD
SCHEMBL1401049 0.78 CTSK (0.46) CYP1A2MEN1LMNAKMT2ACYP2C9
SCHEMBL1401046 0.78 CTSK (0.46) CYP1A2MEN1LMNAKMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207223-B2 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 — — US disclosed
US-20100010222-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-01-14 — — US disclosed
US-7608637-B2 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010222-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT PTGER4, PTGER1, PTGER2 NPSR1 1332/4885MAPT 2797/4885CYP1A2 2146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.